

EFFECT OF XUEBIJING COMBINED WITH ANTIBIOTICS AND FIBEROPTIC BRONCHOSCOPE SPUTUM ASPIRATION AND LAVAGE ON SERUM INFECTION INDEXES AND INFLAMMATORY FACTORS OF ICU PATIENTS WITH SEVERE PNEUMONIA

LIQING PENG[#], QIANFANG LIANG[#], RONG LU, RUIXIANG ZHOU^{*}

Department of Critical Care Medicine, Wuhan No.1 Hospital, Wuhan, 430022, China

[#]The author contributed equally to this article

ABSTRACT

Objective: The purpose was to study the therapeutic effect of Xuebijing combined with antibiotics and fiberoptic bronchoscope sputum aspiration and lavage on ICU patients with severe pneumonia, and analyze its effect on serum infection indexes and inflammatory factors.

Methods: 100 patients with severe pneumonia admitted to ICU of our hospital from January 2018 to December 2019 were randomly selected and divided into control group and experimental group by drawing lots, with 50 cases in each group. The patients in the control group were treated with antibiotics combined with fiberoptic bronchoscope sputum aspiration and lavage while the experimental group was treated with Xuebijing on the basis of the control group to compare the treatment effective rates, incidence of adverse reactions, serum infection indexes (CRP and PCT) and inflammatory factors (IL-6 and IL-8) after treatment between the two groups.

Results: The treatment effective rate in the experimental group was significantly lower than that in the control group, with a statistically significant difference ($P < 0.05$). The incidence of adverse reactions in the experimental group was significantly lower than that in the control group, with a statistically significant difference ($P < 0.05$). The CRP and PCT expression levels in the experimental group were significantly lower than those in the control group after treatment, with statistically significant differences ($P < 0.05$). After treatment, the IL-6 and IL-8 expression levels in the experimental group were significantly lower than those in the control group, with statistically significant differences ($P < 0.05$).

Conclusion: Xuebijing combined with antibiotics and fiberoptic bronchoscope sputum aspiration and lavage has better therapeutic effect on ICU patients with severe pneumonia, which can significantly reduce the expression levels of serum infection indexes and inflammatory factors in patients with severe pneumonia, with high clinical application value.

Keywords: Xuebijing, antibiotics, fibrobronchoscopy, serum infection indexes, inflammatory factors.

DOI: 10.19193/0393-6384_2021_4_388

Received October 15, 2020; Accepted March 20, 2021

Introduction

Pneumonia, as a common respiratory system disease, generally affects the respiratory function of patients, resulting in significantly higher expression levels of inflammatory factors in patients under an inflammatory state⁽¹⁻³⁾. If not treated timely, ordinary pneumonia may develop to severe pneumonia. Severe pneumonia can be caused not only by the development of ordinary pneumonia, but also by some surgically treated patients who have pulmonary

infection after tracheal intubation and then develop into infectious pneumonia⁽⁴⁻⁶⁾. In general, patients with severe pneumonia need intensive care treatment in the ICU of the hospital, focusing on respiratory function and body inflammatory state of the patients. Patients with severe pneumonia often need to use a ventilator for mechanical ventilation, and they will secrete a large amount of sputum. In order to avoid the complications such as cough and pulmonary embolism caused by miss aspiration of sputum, sputum aspiration should be performed

in time. Fibrobronchoscopy is commonly used in clinical practice to assist in sputum aspiration⁽⁷⁻⁹⁾. In addition, due to the increased inflammatory factors in patients with severe pneumonia, antibiotics are necessary in the treatment process to avoid bacterial infection. Xuebijing is an antitoxic inflammatory mediator, which has a better effect on regulating the immune function of patients. Therefore, this paper took patients with severe pneumonia as the research objects to compare the therapeutic effect, adverse reactions, serum infection indexes and inflammatory factors of patients in different groups with or without Xuebijing, specifically reported as follows.

Materials and methods

General information

100 patients with severe pneumonia admitted to ICU of our hospital from January 2018 to December 2019 were randomly selected and divided into control group and experimental group by drawing lots, with 50 cases in each group. The age of patients was 21-60 years old in the experimental group and 20-60 years old in the control group. There was no statistical significance in the comparison of general information such as gender, age and complicated diseases between the two groups ($P>0.05$), as shown in the following table.

Group	Experimental group	Control group	χ^2/t	P
Gender (male/female)	29/21	28/22	0.04	0.84
Age (years old)	46.32±4.47	46.58±4.39	0.29	0.77
Height (cm)	173.35±8.62	173.50±8.55	0.09	0.93
Weight (kg)	71.26±10.20	71.39±10.11	0.06	0.95
Smoking history (years)	3.39±1.28	3.50±1.19	0.45	0.66
Drinking History (years)	6.67±2.08	6.48±2.11	0.45	0.65
Hypertension (number of cases)	6	5	0.10	0.75
Diabetes mellitus (number of cases)	3	5	0.54	0.46
Hyperlipidemia (number of cases)	2	3	0.21	0.65

Table 1: Comparison of general data ($\bar{x}\pm s$).

Inclusion/exclusion criteria

Inclusion criteria:

- The patients had the clinical manifestations of severe pneumonia;
- The patients were aged no less than 18 years old;

- The patients had no circulatory system diseases;
- The patients had no history of drug allergy and drug abuse or bad habits;
- The study was approved by the hospital ethics committee, and all patients voluntarily participated in the study and signed the informed consent.

Exclusion criteria:

- The patients had congenital diseases;
- The patients had consciousness disorder and could not cooperate with the study;
- The patients had severe respiratory diseases recently.

Methods

All patients underwent routine ICU nursing mode with adequate nutritional support to ensure sufficient daily nutrition for patients. Patients were treated according to their condition, and patients with respiratory dysfunction were treated with mechanical ventilation via a ventilator.

Patients in the control group were treated with antibiotics combined with fiberoptic bronchoscope sputum aspiration and lavage. Due to infection by different strains in patients, patients were treated with different antibiotics. Besides, fibrobronchoscopy was used for sputum aspiration. The patients took a supine position, and the pressure of the negative pressure aspirator was adjusted. After its head was lubricated with paraffin oil, the fibrobronchoscopy was inserted from the nasal cavity into the throat and trachea of the patients for sputum aspiration.

Based on the treatment of the control group, patients in the experimental group received 100ml of Xuebijing (manufacturer: Tianjin Chasesun Pharmaceutical Co.,Ltd.; SFDA approval number: Z20040033) with 100ml of normal saline by intravenous drip for 30-40 min, twice a day, and 3-4 times a day in severe cases.

Observation indexes

The treatment effective rate, incidence of adverse reactions, serum infection indexes (CRP and PCT), and inflammatory factors (IL-6 and IL-8) after treatment were compared between the two groups. The patients had no adverse reactions during the treatment process, and inflammation and sputum basically disappeared, which was markedly effective; No adverse reactions occurred, and inflammation and sputum significantly reduced, which was effective; Significant adverse reactions occurred, and inflammation and sputum did not reduce, which was

ineffective. The normal value was 800-8000µg/L for CRP, less than 0.55ng/ml for PCT, 56.37-150.33pg/ml for IL-6 and 0.26-0.38ng/ml for IL-8⁽¹⁰⁻¹²⁾.

Statistical treatment

In this study, SPSS20.0 was selected as the data processing software, and GraphPad Prism 7 (GraphPad Software, San Diego, USA) was used to draw pictures of the data. The study included count data and measurement data. The measurement data were measured by t test, expressed by ($\bar{x}\pm s$), and the count data were tested by X^2 , expressed by [n(%)]. The difference was statistically significant when $p<0.05$.

Results

Comparison of treatment effective rates between the two groups

The comparison of the effective rates between the two groups showed that the treatment effective rate in the experimental group (92%) was significantly higher than that in the control group (76%), with a statistically significant difference ($P<0.05$), as shown in the following table.

Group	Markedly effective	Effective	Ineffective	Total effective rate (%)
Experimental group	27	19	4	92%
Control group	9	29	12	76%
X^2				4.76
P				0.03

Table 2: Comparison of treatment effective rates between the two groups.

Comparison of the incidence of adverse reactions between the two groups

The adverse reactions in the two groups mainly included cough, elevated body temperature and aggravated pneumonia. The incidence of adverse reactions in the experimental group was significantly lower than that in the control group, with a statistically significant difference ($P<0.05$), as shown in the following table.

Group	Cough	Elevated body temperature	Aggravated pneumonia	Total Incidence(%)
Experimental group	2	1	0	6%
Control group	6	7	3	16%
X^2				5.83
P				0.02

Table 3: Comparison of the incidence of adverse reactions between the two groups.

Comparison of serum infection indexes between the two groups

After treatment, the expression levels of serum infection indexes (CRP and PCT) were compared between the two groups.

The CRP and PCT expression levels in the experimental group were significantly lower than those in the control group after treatment, with statistically significant differences ($P<0.05$), as shown in Figure 1 and Figure 2.




Figure 1: Comparison of CRP expression between the two groups.

Note: The abscissa represents experimental group and control group, and the ordinate represents the CRP expression level (µg/L). *indicated the comparison of CRP expression levels between the experimental group (3505.26±168.47) µg/L and the control group (4029.61±153.88) µg/L, with a statistically significant difference ($t=16.25, P<0.001$).

Comparison of inflammatory factors between the two groups

The IL-6 and IL-8 expression levels of serum inflammatory factors in the two groups were compared.

After treatment, the serum IL-6 and IL-8 expression levels in the experimental group were significantly lower than those in the control group, with statistically significant differences ($P<0.05$), as shown in Figure 3 and Figure 4.




Figure 2: Comparison of PCT expression between the two groups.

Note: The abscissa represents experimental group and control group, and the ordinate represents the PCT expression level (ng/ml). *indicated the comparison of PCT expression levels between the experimental group (0.22±0.03) ng/ml and the control group (0.49±0.10) ng/ml, with a statistically significant difference ($t=18.29$, $P<0.001$).




Figure 3: Comparison of IL-6 expression levels between the two groups.

Note: The abscissa represents experimental group and control group, and the ordinate represents the IL-6 expression level (pg/ml). *indicated the comparison of IL-6 expression levels between the experimental group (68.29±8.81)pg/ml and the control group (127.62±11.06)pg/ml, with a statistically significant difference ($t=29.67$, $P<0.001$).




Figure 4: Comparison of IL-8 expression levels between the two groups.

Note: The abscissa represents experimental group and control group, and the ordinate represents the IL-8 expression level (ng/ml). *indicated the comparison of IL-8 expression levels between the experimental group (0.29±0.03)ng/ml and the control group(0.40±0.08)ng/ml, with a statistically significant difference ($t=9.10$, $P<0.001$).

Discussion

Common manifestations of pneumonia include cough, expectoration and loud lung wheezing, which may affect respiratory frequency in severe cases, leading to respiratory failure and respiratory disturbance. If respiratory failure occurs in patients with pneumonia, a ventilator is needed for mechanical ventilation, and they should be immediately transferred to the intensive care unit (ICU) for treatment and nursing. Therefore, patients with severe pneumonia often need to be treated in ICU⁽¹³⁻¹⁵⁾. Since patients with severe pneumonia are often accompanied by a large amount of sputum secretion, complications such as cough, miss aspiration of sputum and infection often occur if the sputum in patients is not cleaned in time⁽¹⁶⁻¹⁹⁾.

Meanwhile, sputum itself is liquid formed by mixing bronchial secretion with dust and impurities in the air, aggravating the patients' condition when staying in the body for long time. Therefore, sputum produced from the trachea, bronchi and the lungs should be promptly cleared in patients with severe pneumonia. Fiberoptic bronchoscope sputum aspiration is a way to absorb the sputum in

the bronchus of patients through fibrobronchoscopy combined with negative pressure device, which is commonly used in clinical practice and often combined with antibiotics for treatment. The main role of antibiotics is to fight against bacteria and reduce the probability of infection in patients⁽²⁰⁻²²⁾. Xuebijing is often used in clinical treatment to deal with toxoinfection and improve immunity. In order to study the application effect of Xuebijing combined with antibiotics and fiberoptic bronchoscope sputum aspiration and lavage in patients with severe pneumonia, this paper took patients with severe pneumonia as the research objects and analyzed the effect of Xuebijing on expression levels of serum infection indexes and inflammatory factors.

The results of this study showed that treatment effective rate and the incidence of adverse reactions in the experimental group treated with Xuebijing combined with antibiotics were significantly better than those in the control group without Xuebijing, with statistically significant differences ($P < 0.05$), indicating that Xuebijing combined with antibiotics and fiberoptic bronchoscope sputum aspiration and lavage can improve the treatment effective rate and reduce the incidence of adverse reactions, so as to provide a relatively safe and effective treatment method for patients. In addition, comparison of the serum infection indexes (CRP and PCT) and inflammatory factors (IL-6 and IL-8) between the two groups showed that the expression levels in the experimental group in this study were all significantly lower than those in the control group, with statistically significant differences ($P < 0.05$), indicating that Xuebijing combined with antibiotics and fiberoptic bronchoscope sputum aspiration and lavage can significantly reduce the expression levels of serum infection indexes and inflammatory factors in patients, and can obviously improve the inflammatory manifestations and reduce the risk of infection-related complications in patients.

Scholars Li Guangwen et al⁽²³⁾ suggested in their study that the serum infection indexes and stress hormone levels of patients with severe pneumonia treated with Xuebijing combined with antibiotics were significantly lower than those of patients treated with antibiotics alone, with statistically significant differences ($P < 0.05$). The conclusion is consistent with the that of this paper as for serum infection indexes of patients, which fully demonstrates the scientificity and reliability of the results in this paper.

In conclusion, Xuebijing combined with antibiotics and fiberoptic bronchoscope sputum

aspiration and lavage has better therapeutic effect on ICU patients with severe pneumonia, which can significantly reduce the expression levels of serum infection indexes and inflammatory factors in patients with severe pneumonia, with high clinical application value. Therefore, it is worthy of promotion and application in clinic.

References

- 1) Xu Zhitong, Lin Jinding, Xie Yongsong, Tang Haifeng, Xie Junjie, Zeng Rongdong. HtrA2 is required for inflammatory responses in BMDMs via controlling TRAF2 stability in collagen-induced arthritis[J]. *Molecular Immunology*, 2021, 129.
- 2) Chugh Heerak, Awasthi Amardeep, Agarwal Yashi, Gaur Rajesh K., Dhawan Gagan, Chandra Ramesh. A comprehensive review on potential therapeutics interventions for COVID-19[J]. *European Journal of Pharmacology*, 2021, 890.
- 3) Robinson Philip C., Liew David F.L., Liew Jean W., Monaco Claudia, Richards Duncan, Shivakumar Senthuran, Tanner Helen L., Feldmann Marc. The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19[J]. *Med*, 2020, 1(1).
- 4) Luo Xia, Wang Xiaojing, Huang Shaowei, Xu Bo, Luo Shuang, Li Yanyang, Wang Qing, Chen Yanping, Deng Xiangliang, Liu Lingyun, Zhou Lian. Paeoniflorin ameliorates experimental colitis by inhibiting gram-positive bacteria-dependent MDP-NOD2 pathway[J]. *International Immunopharmacology*, 2021, 90.
- 5) Siroli Lorenzo, Burns Patricia, Borgo Florencia, Puntillo Melisa, Drago Silvina, Forzani Liliana, D' Alessandro Maria Eugenia, Reinheimer Jorge, Perotti Cristina, Vinderola Gabriel. Sex-dependent effects of a yoghurt enriched with proteins in a mouse model of diet-induced obesity[J]. *International Dairy Journal*, 2021, 114.
- 6) Bobhate Anup, Viswanathan Vijay, Aravindhan Vivekanandhan. Anti-inflammatory cytokines IL-27, IL-10, IL-1Ra and TGF- β in subjects with increasing grades of glucose intolerance (DM-LTB-2)[J]. *Cytokine*, 2021, 137.
- 7) van der Sar - van der Brugge S., Talman S., Boonman - de Winter L.J.M., de Mol M., Hoefman E., van Etten R.W., De Backer I.C.. Pulmonary function and health-related quality of life after COVID-19 pneumonia[J]. *Respiratory Medicine*, 2021, 176.
- 8) Zhao Xiaohui, Jiang Sirong, Dong Qi, Dang Jun, Liu Zenggen, Han Hongping, Tao Yanduo, Yue Huilan. Anti-rheumatoid arthritis effects of iridoid glucosides from *Lamiophlomis rotata* (Benth.) kudo on adjuvant-induced arthritis in rats by OPG/RANKL/NF- κ B signaling pathways[J]. *Journal of Ethnopharmacology*, 2021, 266.

- 9) Scanu Anna, Oliviero Francesca, Luisetto Roberto, Ramonda Roberta, Doria Andrea, Punzi Leonardo, Dayer Jean-Michel. Effect of pathogenic crystals on the production of pro- and anti-inflammatory cytokines by different leukocyte populations[J]. Immunobiology, 2021, 226(1).
- 10) Mody Prapti H., Lucia dos Santos Natalia, Lenert Melissa E., Barron Luz R., Nottingham Bethany A., Burton Michael D.. The role of cap-dependent translation in aged-related changes in neuroimmunity and affective behaviors[J]. Neurobiology of Aging, 2021, 98.
- 11) Choi Kwan Woo, Jang Eun Hye, Kim Ah Young, Kim Hyewon, Park Mi Jin, Byun Sangwon, Fava Maurizio, Mischoulon David, Papakostas George I., Yu Han Young, Jeon Hong Jin. Predictive inflammatory biomarkers for change in suicidal ideation in major depressive disorder and panic disorder: A 12-week follow-up study[J]. Journal of Psychiatric Research, 2021, 133.
- 12) Masala G., Bendinelli B., Della Bella C., Assedi M., Tapinassi S., Ermini I., Occhini D., Castaldo M., Saieva C., Caini S., D'Elia M. M., Palli D.. Inflammatory marker changes in a 24-month dietary and physical activity randomised intervention trial in postmenopausal women[J]. Scientific Reports, 2020, 10(1).
- 13) Jia Xiao Hui, Geng Lu Ying, Jiang Pan Pan, Xu Hong, Nan Ke Jun, Yao Yu, Jiang Li Li, Sun Hong, Qin Tian Jie, Guo Hui. The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors[J]. Journal of Experimental & Clinical Cancer Research, 2020, 39(1).
- 14) Wenxiu Wang, Jun Wu, Mei Ji, Changping Wu. Exogenous interleukin-33 promotes hepatocellular carcinoma growth by remodelling the tumour microenvironment[J]. Journal of Translational Medicine, 2020, 18(1).
- 15) Sakakura Akie, Akashi Yusaku, Shiigai Masanari, Isono Hiroki, Suzuki Hiromichi, Hirose Yumi. A case of severe pneumonia with viremia caused by adenovirus B7 identified by off-label use of a multiplex PCR system[J]. IDCases, 2021, 23.
- 16) Zhang Pei, Wang Maomao, Wang Yang, Wang Yifei, Li Ting, Zeng Jing, Wang Laixing, Li Chunlin, Gong Yanping. Risk factors associated with the progression of COVID-19 in elderly diabetes patients[J]. Diabetes Research and Clinical Practice, 2021, 171.
- 17) Xuan Wang, Sheng Tian, Hansen Wang, Pan Liu, Heqing Zheng, Lanxiang Wu, Qian Liu, Wei Wu. Botulinum toxin type A alleviates neuropathic pain and suppresses inflammatory cytokines release from microglia by targeting TLR2/MyD88 and SNAP23[J]. Cell & Bioscience, 2020, 10(1).
- 18) Two novel coordination polymers: protective activity on acute lung injury via inhibiting the release of inflammatory cytokines in alveolar macrophages[J]. Inorganic and Nano-Metal Chemistry, 2021, 51(2).
- 19) Liu YuLi, Chen YiChun, Chou WenHai, Tsou HsiaoHui, Liu TungHsia, Kuo HsiangWei, Fang ChiuPing, Liu ChiaChen. Alteration of inflammatory factors between chronic stroke and post-stroke dementia: A cross-sectional study[J]. Alzheimer's & Dementia, 2020, 16.
- 20) Chen Jinlian, Zhao Yuxi, Shang Yongpeng, Lin Zhiwei, Xu Guangjian, Bai Bing, Zheng Jinxin, Li Peiyu, Mao Yuanchen, Deng Qiwen, Yu Zhijian. The clinical significance of simultaneous detection of pathogens from bronchoalveolar lavage fluid and blood samples by metagenomic next-generation sequencing in patients with severe pneumonia[J]. Journal of Medical Microbiology, 2020.
- 21) Prevalence of opportunistic invasive aspergillosis in COVID-19 patients with severe pneumonia.[J]. Mycoses, 2020.
- 22) Luo Xiao, Jiaerken Yeerfan, Shen Zhujing, Wang Qiyuan, Liu Bo, Zhou Haisheng, Zheng Hanpeng, Li Yongchou, Gao Yuantong, He Susu, Ji Wenbin, Liu Yongqiang, Ma Jianbing, Mao Longyun, Wang Xiangming, Wang Meihao, Su Miaoguang, Huang Peiyu, Shi Lei, Zhang Minming. Obese COVID-19 patients show more severe pneumonia lesions on CT chest imaging[J]. Diabetes, Obesity and Metabolism, 2020, 23(1).
- 23) Li Guangwen, Du Hanjie. The effect of Xuebijing adjuvant therapy on serum infection indexes and serum acute protein and stress hormone levels in ICU patients with severe pneumonia [J]. Clinical medicine, 2019, 39(12): 82-84.

Corresponding Author:

RUIXIANG ZHOU

Department of Critical Care Medicine, Wuhan No.1 Hospital, No.215 Zhongshan Road, Qiaokou District, Wuhan, 430022, Hubei Province, China

Email: 905838703@qq.com

(China)